-
CDK Verwandte Produkte (490)
Verwandte Produkte (490)
-
(E/Z)-THZ1 dihydrochloride
0 ImagesArt. -Nr.: HY-80013BCAS. Nr.: 2095433-94-4(E/Z)-THZ1 dihydrochloride is a selective inhibitor of CDK7 with an IC50 of 3.2 nM. (E/Z)-THZ1 dihydrochloride has antiproliferative effect.
-
2,4,6-Trihydroxybenzoic acid (Standard)
0 Images2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer.
-
AT7519 Hydrochloride (Standard)
0 ImagesAT7519 (Hydrochloride) (Standard) is the analytical standard of AT7519 (Hydrochloride). This product is intended for research and analytical applications. AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
-
(S)-(-)-O-Demethylbuchenavianine
0 ImagesArt. -Nr.: HY-N12625ACAS. Nr.: 91147-18-1
-
CDK4-IN-1
0 ImagesArt. -Nr.: HY-15612CAS. Nr.: 1256963-02-6CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
-
1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC
0 ImagesSynonyms: PC(18:0/22:4)1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) is an inhibitor of cyclin-dependent kinases (CDKs). 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC induces apoptosis and inhibits the growth of various cancer cell lines.
-
Ribociclib succinate (Standard)
0 ImagesSynonyms: LEE011 succinate (Standard)Ribociclib succinate (Standard) is the analytical standard of Ribociclib succinate. This product is intended for research and analytical applications. Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
-
Cdc7-IN-4
0 ImagesArt. -Nr.: HY-130516CAS. Nr.: 1402059-21-5Cdc7-IN-4 (compound I-C) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
-
Tibremciclib
0 ImagesArt. -Nr.: HY-156646CAS. Nr.: 2397678-18-9Synonyms: BPI-16350Tibremciclib is a CDK4 inhibitor with antineoplastic activity.
-
rel-AZ5576
0 ImagesArt. -Nr.: HY-111537CAS. Nr.: 1333468-05-5rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.
-
CDK9-IN-29
0 ImagesArt. -Nr.: HY-149641CAS. Nr.: 2737262-24-5
-
Cdc7-IN-3
0 ImagesArt. -Nr.: HY-130515CAS. Nr.: 1402057-87-7Cdc7-IN-3 (compound I-A) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
-
Cdc7-IN-7
0 ImagesCdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
-
QR-6401
0 ImagesArt. -Nr.: HY-153221CAS. Nr.: 2845096-18-4QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer.
-
CDK-IN-13
0 ImagesArt. -Nr.: HY-157297CAS. Nr.: 3041994-96-8CDK-IN-13 (compound 32E) is a potent and selective inhibitor of CDK12/cyclinK with an IC50 of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines.
-
AGM-130
0 ImagesArt. -Nr.: HY-114248CAS. Nr.: 1459216-10-4AGM-130 is a cyclin-dependent kinase (CDK) inhibitor. AGM-130 exhibits antitumor activity.
